Skip to main content

Table 1 Patients and disease characteristics

From: The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years—a report from the EBMT acute leukemia working party

Patient characteristics HLA 10/10 HLA 9/10 HLA 8/10 p value
Number of patients 2567 723 108  
Recipient age at SCT (years, range) 61 (50–78) 61 (50–77) 60 (50–73) 0.584
Recipient gender, n (%) 0.707
 Male 1386 (54 %) 387 (53.7 %) 62 (58 %)  
 Female 1177 (46 %) 334 (46.3 %) 45 (42 %)  
Year of SCT (median), year (%) 2011 (00–13) 2011 (02–13) 2009 (00–13) 0.001
Interval from diagnosis to SCT (days) 212 250 295 0.0001
Median follow-upa (months, range) 24 (1–150) 24 (1–139) 34 (3–117) 0.042
Donor age (years, range) 33 (16–61) 36 (20–61) 35 (20–55) 0.02
Donor gender, n (%) <10−4
 Male 1845 (73 %) 463 (65.2 %) 69 (64.5 %)  
 Female 682 (27 %) 247 (34.8 %) 38 (35.5 %)  
Female donor to male recipient, n (%) 281 (11.1 %) 106 (15 % ) 17 (16 % ) 0.01
Diagnosis, n (%) 0.001
 De novo AML 1805 (70.3 %) 527 (72.9 %) 60 (55.6 %)  
 Secondary AML 762 (29.7 %) 196 (27.1 %) 48 (44.4 %)  
Cytogenetics in de novo AML, n (% of available data) 0.235
 Good 75 (9.2 %) 15 (5.9 %) 2 (7.1 %)  
 Intermediate 545 (67.2 %) 183 (72 %) 23 (82 %)  
 Poor 191 (23.5 %) 56 (22 %) 3 (10.7 %)  
 Not available/failed 994 (55 %) 273 (51.8 %) 32 (53.3 %)  
Disease status at SCT, n (%)     0.0002
 CR1 1413 (55 %) 333 (46.1 %) 48 (44.4 %)  
 ≥CR2 504 (19.7 %) 171 (23.6 %) 25 (23.2 %)  
 Active disease 650 (25.3 %) 219 (30.3 %) 35 (32.4 %)  
Source of SC, n (%) 0.173
 BM 154 (6 %) 56 (7.8 %) 9 (8.3 %)  
 PB 2413 (94 %) 667 (92.2 %) 99 (91.7 %)  
Conditioning, n (%) 0.02
 Chemo alone 1836 (71.5 %) 550 (76.1 %) 84 (77.8 %)  
 Low TBI 731 (28.5 %) 173 (23.9 %) 24 (22.2 %)  
In vivo T cell depletion, n (%) <10−4
 No 672 (26.4 %) 121 (16.9 %) 15 (14.0 %)  
 ATG 1460 (57.5 %) 468 (65.2 %) 59 (55.1 %)  
 Campath 409 (16.1 %) 129 (18.0 %) 33 (30.8 %)  
Post-transplant GVHD prophylaxis     0.07
 CsA 504 (19.9 %) 135 (18.8 %) 27 (25.5 %)  
 CsA/FK 506 + MTX 517 (20.4 %) 177 (24.7 %) 16 (15.1 %)  
 CsA/FK 506 + MMF 1353 (53.4 %) 353 (49.2 %) 53 (50 %)  
 Other 160 (6.3 %) 53 (7.4 %) 10 (9.4 %)  
 Missing 33 5 2  
Karnosky at SCT, n (%)     0.47
 ≤80 % 173 (6.7 %) 42 (5.8 %) 9 (8.4 %)  
 >80 % 2231 (86.9 %) 641 (88.7 %) 91 (84.2 %)  
 Missing 163 (6.4 %) 40 (5.5 %) 8 (7.4 %)  
Patient positive CMV serology, n (%) 1634 (64.9 %) 492 (69.1 %) 67 (63.8 %) 0.10
CMV risk, n (%)     0.029
 Low 695 (27.8 %) 155 (21.9 %) 26 (24.8 %)  
 Intermediate 1072 (42.8 %) 316 (44.7 %) 47 (44.8 %)  
 High 734 (29.4 % ) 236 (33.4 %) 32 (30.5 %)  
  1. AML acute myeloid leukemia, ATG anti-thymocyte globulin, BM bone marrow, CMV cytomegalovirus, CMV risk low = negative recipient and donor serology, high positive recipient and negative donor serology, intermediate all other combinations, CR complete remission, PB peripheral blood, SC stem cells, SCT stem cell transplantation
  2. aFor patients alive